# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-09-2024 | 03-31-2024 | 10-Q | |
2 | 03-15-2024 | 12-31-2023 | 10-K | |
3 | 11-14-2023 | 09-30-2023 | 10-Q | |
4 | 08-14-2023 | 06-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndromeTopical application of ATR-12 to ex vivo...
Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 r...
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confid...
Financial Results for the Year Ended December 31, 2023 Service Revenue – Related Party: The Company generated $0.7 million o...